Ranked #1
Pomalidomide prolongs survival in refractory multiple myeloma patients: Dr Jesus San Miguel
Pomalidomide prolongs survival in refractory multiple myeloma patients: Dr Jesus San Miguel
Prof Jesus San Miguel talks with ecancer at the 18th EHA Congress about the MM-003 trial.MM-003 is a large, multi-centre... Read more
20 Jun 2013
•
7mins
Ranked #2
Long-term outcomes with ruxolitinib and best available therapy for the treatment of myelogibrosis: Dr Alessandro Vannucchi
Long-term outcomes with ruxolitinib and best available therapy for the treatment of myelogibrosis: Dr Alessandro Vannucchi
Prof Alessandro Vannucchi talks to ecancer at the 18th EHA Congress in Stockholm about a phase III clinical trial that e... Read more
20 Jun 2013
•
8mins
Ranked #3
Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic leukaemia: Dr Valentin Go
Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic leukaemia: Dr Valentin Go
Dr Valentin Goede presented promising outcomes for elderly CLL patients at the 18th Congress of the European Hematology ... Read more
20 Jun 2013
•
4mins
Ranked #4
Rituximab for b-cell lymphoma and EHA overview: Prof Ulrich Jäger
Rituximab for b-cell lymphoma and EHA overview: Prof Ulrich Jäger
President of the European Haematology Association talks to ecancer at the 18th EHA Congress about developments arising f... Read more
20 Jun 2013
•
9mins
Most Popular Podcasts
The Joe Rogan Experience
TED Talks Daily
The Tim Ferriss Show
The Daily
Stuff You Should Know
Oprah's SuperSoul Conversations
Armchair Expert with Dax Shepard
Ranked #5
Challenges facing haematologists treating acute myeloid leukaemia
Challenges facing haematologists treating acute myeloid leukaemia
Dr Dalia Mahmoud talks to ecancer at the 18th EHA Congress about treating acute myeloid leukaemia, availability of azacy... Read more
20 Jun 2013
•
6mins
Ranked #6
Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma: Prof Heinrich Lokhorst
Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma: Prof Heinrich Lokhorst
Prof Heinrich Lokhorst talks to ecancer at EHA 18 about results from a phase I/II study in advanced Multiple Myeloma.Mul... Read more
20 Jun 2013
•
4mins
Ranked #7
Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma: Dr Annamaia Brioli
Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma: Dr Annamaia Brioli
Dr Annamaria Brioli talks to ecancer at the 18th EHA Congress in Stockholm, Sweden about two studies that examine the us... Read more
20 Jun 2013
•
4mins
Ranked #8
Patient advocacy track 'personalised medicine': Prof Anton Hagenbeek
Patient advocacy track 'personalised medicine': Prof Anton Hagenbeek
Prof Anton Hagenbeek talks to ecancer at the patient advocacy track, availability of drugs, communication with pharmaceu... Read more
20 Jun 2013
•
6mins
Ranked #9
Second line treatment of multiple myeloma with melphalan prednisone and lenalidomide: Prof Meletios Dimopoulos
Second line treatment of multiple myeloma with melphalan prednisone and lenalidomide: Prof Meletios Dimopoulos
Prof Meletios Dimopoulos talks to ecancer at the 18th EHA Congress in Stockholm, Sweden about second generation drugs fo... Read more
20 Jun 2013
•
3mins
Ranked #10
Strategies to maintain remission in high risk CD19 lymphoid malignancies: Dr Partow Kebriaei
Strategies to maintain remission in high risk CD19 lymphoid malignancies: Dr Partow Kebriaei
Dr Partow Kebriaei talks to ecancer at the 18th EHA Congress about her abstract on artificial antigen presenting cells t... Read more
20 Jun 2013
•
5mins
